Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
Phase I, Open Label, Non-randomised, Non-comparative, Multi-center Study, Evaluating S65487, a Bcl-2 Inhibitor Intravenously Administered, in Patients With Relapse or Refractory Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Commercial Sponsor
Servier
Summary
This study is designed in two parts: one part for dose escalation and one part for dose expansion. S65487 will be administered as single agent via intravenous infusion on a 3-week cycle. Once dose escalation is complete, dose expansion will commence at the maximum tolerated or recommended phase 2 dose.